Literature DB >> 16942444

Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.

Samuel G Jacobson1, Sanford L Boye, Tomas S Aleman, Thomas J Conlon, Caroline J Zeiss, Alejandro J Roman, Artur V Cideciyan, Sharon B Schwartz, Andras M Komaromy, Michelle Doobrajh, Andy Y Cheung, Alexander Sumaroka, Susan E Pearce-Kelling, Gustavo D Aguirre, Shalesh Kaushal, Albert M Maguire, Terence R Flotte, William W Hauswirth.   

Abstract

Leber congenital amaurosis (LCA) is a molecularly heterogeneous disease group that leads to blindness. LCA caused by RPE65 mutations has been studied in animal models and vision has been restored by subretinal delivery of AAV-RPE65 vector. Human ocular gene transfer trials are being considered. Our safety studies of subretinal AAV-2/2.RPE65 in RPE65-mutant dogs showed evidence of modest photoreceptor loss in the injection region in some animals at higher vector doses. We now test the hypothesis that there can be vectorrelated toxicity to the normal monkey, with its human-like retina. Good Laboratory Practice safety studies following single intraocular injections of AAV-2/2.RPE65 in normal cynomolgus monkeys were performed for 1-week and 3-month durations. Systemic toxicity was not identified. Ocular-specific studies included clinical examinations, electroretinography, and retinal histopathology. Signs of ocular inflammation postinjection had almost disappeared by 1 week. At 3 months, electroretinography in vector-injected eyes was no different than in vehicle-injected control eyes or compared with presurgical recordings. Healed sites of retinal perforation from subretinal injections were noted clinically and by histopathology. Foveal architecture in subretinally injected eyes, vector or vehicle, could be abnormal. Morphometry of central retina showed no photoreceptor layer thickness abnormalities occurring in a dose-dependent manner. Vector sequences were present in the injected retina, vitreous, and optic nerve at 1 week but not consistently in the brain. At 3 months, there were no vector sequences in optic nerve and brain. The results allow for consideration of an upper range for no observed adverse effect level in future human trials of subretinal AAV-2/2.RPE65. The potential value of foveal treatment for LCA and other retinal degenerations warrants further research into how to achieve gene transfer without retinal injury from surgical detachment of the retina.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16942444     DOI: 10.1089/hum.2006.17.845

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  69 in total

1.  Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina.

Authors:  Elodie Touchard; Marianne Berdugo; Pascal Bigey; Mohamed El Sanharawi; Michèle Savoldelli; Marie-Christine Naud; Jean-Claude Jeanny; Francine Behar-Cohen
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

Review 2.  Gene therapy for ocular diseases.

Authors:  Melissa M Liu; Jingsheng Tuo; Chi-Chao Chan
Journal:  Br J Ophthalmol       Date:  2010-08-23       Impact factor: 4.638

3.  A 350 bp region of the proximal promoter of Rds drives cell-type specific gene expression.

Authors:  Xue Cai; Shannon M Conley; Tong Cheng; Muayyad R Al-Ubaidi; Muna I Naash
Journal:  Exp Eye Res       Date:  2010-05-04       Impact factor: 3.467

4.  Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection.

Authors:  Thomas J Giove; Miguel Sena-Esteves; William D Eldred
Journal:  Exp Eye Res       Date:  2010-08-17       Impact factor: 3.467

Review 5.  Gene therapy for Leber congenital amaurosis: advances and future directions.

Authors:  Robert B Hufnagel; Zubair M Ahmed; Zélia M Corrêa; Robert A Sisk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-29       Impact factor: 3.117

6.  Gene Therapy for MERTK-Associated Retinal Degenerations.

Authors:  Matthew M LaVail; Douglas Yasumura; Michael T Matthes; Haidong Yang; William W Hauswirth; Wen-Tao Deng; Douglas Vollrath
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

7.  Intravitreal delivery of a novel AAV vector targets ON bipolar cells and restores visual function in a mouse model of complete congenital stationary night blindness.

Authors:  Miranda L Scalabrino; Sanford L Boye; Kathryn M H Fransen; Jennifer M Noel; Frank M Dyka; Seok Hong Min; Qing Ruan; Charles N De Leeuw; Elizabeth M Simpson; Ronald G Gregg; Maureen A McCall; Neal S Peachey; Shannon E Boye
Journal:  Hum Mol Genet       Date:  2015-08-26       Impact factor: 6.150

Review 8.  RPE65: role in the visual cycle, human retinal disease, and gene therapy.

Authors:  Xue Cai; Shannon M Conley; Muna I Naash
Journal:  Ophthalmic Genet       Date:  2009-06       Impact factor: 1.803

9.  Somatic Gene Editing of GUCY2D by AAV-CRISPR/Cas9 Alters Retinal Structure and Function in Mouse and Macaque.

Authors:  K Tyler McCullough; Sanford L Boye; Diego Fajardo; Kaitlyn Calabro; James J Peterson; Christianne E Strang; Dibyendu Chakraborty; Sebastian Gloskowski; Scott Haskett; Steven Samuelsson; Haiyan Jiang; C Douglas Witherspoon; Paul D Gamlin; Morgan L Maeder; Shannon E Boye
Journal:  Hum Gene Ther       Date:  2018-12-20       Impact factor: 5.695

10.  The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina.

Authors:  Shannon E Boye; John J Alexander; Sanford L Boye; Clark D Witherspoon; Kristen J Sandefer; Thomas J Conlon; Kirsten Erger; Jingfen Sun; Renee Ryals; Vince A Chiodo; Mark E Clark; Christopher A Girkin; William W Hauswirth; Paul D Gamlin
Journal:  Hum Gene Ther       Date:  2012-09-20       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.